Background
Ovarian cancer (OC) is occult, 70% of OC patients are advanced at first visit, the recurrence rate is 70% within 3 years after initial treatment, and the 5-year survival rate of advanced OC patients is only about 40%[1] .The main reason is that patients are prone to early distant metastasis, and at the same time, they are prone to resistance to platinum drugs in the later stage of chemotherapy[2] .Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecological tumors[3] ,High-grade serous carcinoma(High-grade serous carcinoma,HGSC)is the most common histology in EOC.Subtype.Despite significant advances in the treatment of epithelial ovarian cancer in the past few decades, recurrent ovarian cancer remains a fatal disease, often controlled by combined treatment with surgery and chemotherapy[4] .Because the clinical needs of these patients are arguably the greatest, our focus is on treating advanced disease. Through continued progress, we hope that ovarian cancer will transition from a highly fatal disease to a chronic but treatable disease and gradually become a curable disease.
Aidi injection is mainly composed of astragalus root, ginseng, acanthopanax root, etc.In ovarian cancer, it mainly lies in inhibiting tumor angiogenesis by down-regulating vascular endothelial growth factor[5] , reduce the expression of proteins encoded by carcinogenic active genes, thereby producing anti-tumor effects[6] .The compound matrine injection is mainly composed of matrine and oxymatrine (also known as matrine). This kind of alkaloid has many pharmacological activities, among which the most significant one is antitumor activity[7] .Its main effects include inhibition of cell proliferation, induction of apoptosis and autophagy, inhibition of cell migration and invasion, inhibition of tumor angiogenesis, reversal of multidrug resistance of tumor cells and regulation of immunity[8-13] .
Although the use of Aidi combined with Sophora flavescens as a treatment for ovarian cancer is not fully understood, it offers promise as a complementary therapy. Here, we present a study of patients with advanced recurrent ovarian cancer treated with Aidi combined with Sophora flavescens for prevention of recurrence and metastasis. This treatment resulted in 86 months of progression-free survival (PFS) after chemotherapy for ovarian cancer, complete remission after palliative chemotherapy for recurrence and metastasis, The median progression-free survival (PFS) of 9.2 months was well exceeded[14] .